On Tuesday, the Federal Operators gave green signal to the VisionCare Ophthalmic Technologies’ unique implantable eye telescope for aged people suffering from an advanced form of age-related macular degeneration.

The Saratoga Company’s device has been designed to help about 750,000 people in the United States who experience the most intense and untreatable form of the disease, resulting in a blind spot in the center of vision of the patients.

After approving the device, Dr. Jeffrey Shuren, Director of the Center for Devices and Radiological Health at the U. S. Food and Drug Administration, said the innovative creation will help people suffering from this disorder lead an improved and quality life.

The acceptance has been celebrated by this private Company, as it has been working on this project since ten years. Earlier in the year 2006, the device was not allowed for use on account of some safety reasons by an FDA advisory panel. Following this, VisionCare conducted some more studies to prove the discovery and finally, the panel approved it.

VisionCare has raised $59 million since its foundation in 1997, and it has been under consistent loss because it does not have any other products in the market.

Chet Kumar, VisionCare's Vice President for Business and Market Development, said the Company is now expecting to make profit with the sanction of the telescope.